首页 > 市场调查报告书 > 製药

感染疾病

市场调查报告书

商品编码

1085791

急性阴道念珠菌病治疗的全球市场：药物类型、给药途径、分销渠道、区域规模、份额、前景、机会分析（2022-2028 年）

Acute Vulvovaginal Candidiasis Treatment Market, by Drug Type, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日期: 2022年05月22日 | 出版商:

Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3个工作天内

价格

简介目录

市场公司致力于拓展其产品组合、加强其在全球市场中的地位以及预计将在预测期内推动全球市场增长的收购等无机活动。此外，外阴阴道念珠菌病治疗开发的研发力度加大，预计将在预测期内推动全球急性外阴阴道念珠菌病治疗市场的增长。

本报告研究和分析了全球急性外阴念珠菌病治疗市场，并提供了市场概况、市场动态、趋势、竞争形势和企业概况等系统信息。

Acute vulvovaginal candidiasis is a yeast infection, which affects the vagina and tissues present at the opening of the vulva. It is caused by fungus Candida species. The symptoms for the infection are intense itchiness, inflammation, thick, white discharge, and others. Mild infection can be cured with a single dose of the antifungal agent or by application of antifungal creams while severe infections require longer treatment.

Market Dynamics

Market players are indulged in inorganic activities such as acquisition, which is expected to expand their product portfolio and strengthen their position in the global market, and drive growth of the global market over the forecast period. For instance, on June 7, 2022, ANI Pharmaceuticals Inc. acquired Fluconazole Tablets (50mg, 100mg, 150mg, and 200mg) from a private company for US$ 3 million. Thus, ANI Pharmaceuticals expanded their product portfolio by including drugs for the treatment of acute vulvovaginal candidiasis.

Increasing research and development for developing treatment for vulvovaginal candidiasis is expected to drive growth of the global acute vulvovaginal candidiasis treatment market over the forecast period. For instance, according to the article published in the BMC Microbiology Journal: 2018, Nystatin, an oral medication for the treatment of vulvovaginal candidiasis, when used in the vaginal epithelial cells (VEC) infected with Candidiasis albicans, increased the levels of IFN-γ, IL-17, and IgG in the cells as compared to the uninfected cells. Therefore, Nystatin upregulates the host defense mechanism against Candida albicans.

Key features of the study:

This report provides an in-depth analysis of global acute vulvovaginal candidiasis treatment market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global acute vulvovaginal candidiasis treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Mycovia Pharmaceuticals, Inc., Scynexis, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global acute vulvovaginal candidiasis treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the acute vulvovaginal candidiasis treatment market

Detailed Segmentation:

Global Acute Vulvovaginal Candidiasis Treatment Market, By Drug Type:
- Clotrimazole
- Nystatin
- Fluconazole
- Ketoconazole
- Terbinafine
- Terconazole
- Others
Global Acute Vulvovaginal Candidiasis Treatment Market, By Route of Administration:
- Oral
- Intravenous
- Topical
Global Acute Vulvovaginal Candidiasis Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Acute Vulvovaginal Candidiasis Treatment Market, By Region:
- North America
By Country
- U.S.
- Canada
By Drug Type:
- Clotrimazole
- Nystatin
- Fluconazole
- Ketoconazole
- Terbinafine
- Terconazole
- Others
By Route of Administration
- Oral
- Intravenous
- Topical
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America
By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
By Drug Type:
- Clotrimazole
- Nystatin
- Fluconazole
- Ketoconazole
- Terbinafine
- Terconazole
- Others
By Route of Administration
- Oral
- Intravenous
- Topical
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
By Drug Type:
- Clotrimazole
- Nystatin
- Fluconazole
- Ketoconazole
- Terbinafine
- Terconazole
- Others
By Route of Administration
- Oral
- Intravenous
- Topical
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia Pacific
By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
By Drug Type:
- Clotrimazole
- Nystatin
- Fluconazole
- Ketoconazole
- Terbinafine
- Terconazole
- Others
By Route of Administration
- Oral
- Intravenous
- Topical
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Middle East
By Country:
- GCC
- Israel
- Rest of Middle East
By Drug Type:
- Clotrimazole
- Nystatin
- Fluconazole
- Ketoconazole
- Terbinafine
- Terconazole
- Others
By Route of Administration
- Oral
- Intravenous
- Topical
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Africa
By Country/Region:
- South Africa
- Central Africa
- North Africa
By Drug Type:
- Clotrimazole
- Nystatin
- Fluconazole
- Ketoconazole
- Terbinafine
- Terconazole
- Others
By Route of Administration
- Oral
- Intravenous
- Topical
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Company Profiles
Mycovia Pharmaceuticals, Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
Scynexis, Inc.
Basilea Pharmaceutica Ltd.
Astellas Pharma Inc.
Grupo Ferrer Internacional, S.A.
Pacgen Life Science Corporation
NovaDigm Therapeutics, Inc.
Cidara Therapeutics, Inc.
Amplyx Pharmaceuticals Inc.
Pfizer, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Epidemiology
Key Developments
Regulatory Scenario
Reimbursement Scenario
PEST Analysis
Market Share Analysis
Brand Analysis

4. Global Acute Vulvovaginal Candidiasis Treatment Market - Impact of Coronavirus COVID - 19 Impact

During COVID-19 Market Situation
Supply Side and Demand Side Analysis
Impact of COVID-19 on Acute Vulvovaginal Candidiasis Treatment Market
Government Initiatives to Combat COVID-19

5. Global Acute Vulvovaginal Candidiasis Treatment Market, By Drug Type, 2017 - 2028 (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Clotrimazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Nystatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Fluconazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Ketoconazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Terbinafine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Terconazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Acute Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2017 - 2028 (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Acute Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2017 - 2028 (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

8. Global Acute Vulvovaginal Candidiasis Treatment Market, By Region, 2017 - 2028 (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2028
- Regional Trends
North America
- Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- U.S.
- Canada
Latin America
- Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
Africa
- Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country/Region, 2017 - 2028 (US$ Mn)
- South Africa
- Central Africa
- North Africa

9. Competitive Landscape

Company Profiles
- Mycovia Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Scynexis, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Basilea Pharmaceutica Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Astellas Pharma Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Grupo Ferrer Internacional, S.A
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Pacgen Life Science Corporation
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- NovaDigm Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Cidara Therapeutics, Inc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Amplyx Pharmaceuticals Inc.,
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
Analyst Views

10. Section

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

急性阴道念珠菌病治疗的全球市场：药物类型、给药途径、分销渠道、区域规模、份额、前景、机会分析（2022-2028 年）

Acute Vulvovaginal Candidiasis Treatment Market, by Drug Type, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目录

第 1 章调查目标/先决条件

第二章市场概述

第三章市场动态/监管/趋势分析

第 4 章全球急性外阴念珠菌病治疗市场：冠状病毒 COVID-19 大流行影响

第 5 章全球急性外阴念珠菌病治疗市场：按药物类型（2017-2028 年）

第 6 章全球急性外阴念珠菌病治疗市场：按给药途径（2017-2028）

第 7 章全球急性外阴念珠菌病治疗市场：按分销渠道（2017-2028 年）

第 8 章全球急性外阴念珠菌病治疗市场：按地区（2017-2028 年）

第9章竞争态势

第10章章节